Diffusion
DFFN

From January 1, 2023 to March 31, 2023 Stock-based compensation expense and vesting of restricted stock units

From January 1, 2022 to December 31, 2022 Conversion of Series C preferred stock to common stock Stock-based compensation expense and vesting of restricted stock units Sale of Series C preferred stock to related parties

From July 1, 2022 to September 30, 2022 Stock-based compensation expense and vesting of restricted stock units

From April 1, 2022 to June 30, 2022 Conversion of Series C preferred stock to common stock Stock-based compensation expense and vesting of restricted stock units

Diffusion Pharmaceuticals Inc. today announced that it will effect a 1-for-50 reverse stock split of its common stock. The reverse stock split is expected to become effective at 5:59 p.m. Eastern Time on April 18, 2022. The reverse stock split will reduce the Company’s number of shares outstanding common stock from approximately 102 million shares to approximately 2 million shares.

From December 31, 2020 to December 31, 2021 Issuance of common stock upon exercise of warrants, net of issuance costs Issuance of common stock upon exercise of warrants Vesting of restricted stock units

From December 31, 2020 to March 12, 2021 Issuance of common stock upon exercise of warrants, net of issuance costs

1.Common stock offered by the company 29,268,294 Shares. 2.The number of shares of common stock to be outstanding after this offering is based on 68,018,555 shares of common stock outstanding as of February 10, 2021.

From July 1, 2020 to September 30, 2020 Issuance of common stock upon exercise of warrants

From April 1, 2020 to June 30, 2020 Issuance of common stock and warrants, net of issuance costs Issuance of common stock upon exercise of warrants

1.Shares of common stock offered by us 11,428,572 shares 2.The number of shares of our common stock to be outstanding after this offering is based on 47,821,992 shares of common stock outstanding as of May 15, 2020

From January 1, 2020 to March 12, 2020 Issuance of common stock upon exercise of warrants, net

from December 31, 2018 to December 31, 2019 Issuance of common stock, pre-funded warrants and warrants, net of issuance costs Proceeds from warrants

The Company offering 5,104,429 Class A Units with each Class A Unit at a public offering price of $0.35 per Class A Unit consisting of one share of our common stock, one Series I Warrant to purchase one share of our common stock and one Series II Warrant to purchase one share of our common stock. The Class A Units will not be certificated and the share of common stock, the Series I Warrant and Series II Warrant comprising such unit are immediately separable and will be issued separately in this offering.

from March 31, 2019 to June 30, 2019 Issuance of common stock and warrants, net of issuance costs

From December 31, 2017 to December 31, 2018 Conversion of Series A convertible preferred stock to common stock Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature Issuance of common stock related to accrued dividends Issuance of common stock and warrants, net of issuance costs Common stock issued for advisory services

The Company's stockholders approved the reverse stock split on June 14, 2018 and the Company's Board of Directors the reverse stock split ratio on November 30, 2018. At the effective time of the reverse stock split, every 15 shares of Diffusion issued and outstanding common stock were automatically combined and converted into 1 issued and outstanding share of common stock without any change in the par value of the shares. This has reduced the number of outstanding shares of common stock from approximately 50.6 million to approximately 3.4 million.

From January 1, 2018 to June 30, 2018 Conversion of Series A convertible preferred stock to common stock Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature Issuance of common stock related to accrued dividends Issuance of common stock and warrants, net of issuance costs Common stock issued for advisory services

From January 1, 2018 to March 31, 2018 Conversion of Series A convertible preferred stock to common stock Issuance of common stock to Series A convertible preferred stockholders under make-whole adjustment feature Issuance of common stock related to accrued dividends Issuance of common stock and warrants, net of issuance costs

On January 22, 2018, Diffusion Pharmaceuticals Inc. (the “Company”) closed its previously announced underwritten public offering of 15,000,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), and warrants to purchase 15,000,000 shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional 1,970,625 shares of Common Stock pursuant to the underwriter’s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of $0.80 per share and warrant for total gross proceeds of approximately $12.0 million. The warrants have an exercise price of $0.80 per share and a term of five years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to 750,000 shares of Common Stock. The underwriter’s warrants have an exercise price of $1.00, a term of five years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company's Series A convertible preferred stock converted into 20,568,632 shares (the "Conversion Shares) of common stock (including accrued dividends paid in kind and the "make-whole" adjustment feature thereof).

From January 1, 2017 to December 31, 2017 Common stock issued for advisory services Reclassification of accrued dividends upon conversion of Series A Conversion of Series A convertible preferred stock to common stock

From January 1, 2017 to September 30, 2017 Sale of Series A convertible preferred stock and common stock warrants Conversion of Series A convertible preferred stock to common stock Reclassification of accrued dividends upon conversion of Series A

from January 1, 2017 to June 30, 2017 Sale of Series A convertible preferred stock and common stock warrants Conversion of Series A convertible preferred stock to common stock

from January 1, 2017 to March 31, 2017 Sale of Series A convertible preferred stock and common stock warrants

From January 1, 2016 to September 30, 2016 Fair value of RestorGenex shares Common stock issued for advisory services Conversion of convertible debt